- Health
- Viruses, Infections & Disease
- Alzheimers & Dementia
In people destined to get Alzheimer's in their mid-40s, one protein can delay the onset of the disease by about 20 years.
When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works.
A daughter holds the arm of her father, who has Alzheimer's disease. Many people in this region of Colombia have a gene mutation, called presenilin 1 (PSEN1), that leads them to develop Alzheimer's in their mid-40s.
(Image credit: RAUL ARBOLEDA / Stringer via Getty Images)
Page 1 of 2:
Page 1
- Page 1
- Page 2
- Copy link
- X
Get the world’s most fascinating discoveries delivered straight to your inbox.
Become a Member in Seconds
Unlock instant access to exclusive member features.
Contact me with news and offers from other Future brands Receive email from us on behalf of our trusted partners or sponsors By submitting your information you agree to the Terms & Conditions and Privacy Policy and are aged 16 or over.You are now subscribed
Your newsletter sign-up was successful
Want to add more newsletters?
Delivered Daily
Daily Newsletter
Sign up for the latest discoveries, groundbreaking research and fascinating breakthroughs that impact you and the wider world direct to your inbox.
Signup +
Once a week
Life's Little Mysteries
Feed your curiosity with an exclusive mystery every week, solved with science and delivered direct to your inbox before it's seen anywhere else.
Signup +
Once a week
How It Works
Sign up to our free science & technology newsletter for your weekly fix of fascinating articles, quick quizzes, amazing images, and more
Signup +
Delivered daily
Space.com Newsletter
Breaking space news, the latest updates on rocket launches, skywatching events and more!
Signup +
Once a month
Watch This Space
Sign up to our monthly entertainment newsletter to keep up with all our coverage of the latest sci-fi and space movies, tv shows, games and books.
Signup +
Once a week
Night Sky This Week
Discover this week's must-see night sky events, moon phases, and stunning astrophotos. Sign up for our skywatching newsletter and explore the universe with us!
Signup +Join the club
Get full access to premium articles, exclusive features and a growing list of member rewards.
Explore An account already exists for this email address, please log in. Subscribe to our newsletterA single gene mutation protects against Alzheimer's disease in people destined to get the disease very young — and now we know why.
The gene mutation affects a protein called reelin that directs brain cells to shred the probable culprits in the disease — toxic amyloid plaques and tau tangles. The mutation makes reelin work much more efficiently, new research reveals.
Article continues below You may like-
Inherited diseases don't work like we thought they did
-
From gene therapy breakthroughs to preventable disease outbreaks: The health trends that will shape 2026
-
Groundbreaking new drug shows promise for treating children with a devastating form of epilepsy
A tale of two genes
Unpacking how the protective mutation worked began with a population that faced the opposite problem: an extraordinarily harmful mutation that accelerates Alzheimer's disease.
For decades, people in the lush valleys near Medellin, Colombia, had faced premature memory loss.
Neurologist Dr. Francisco Lopera grew up in the region. While he was still a medical student, he came across his first case, a 47-year-old man displaying memory symptoms usually seen in elderly people with dementia. Lopera traveled across the region, determined to map where people were facing early memory loss. He ultimately identified thousands of people affected by a rare genetic form of Alzheimer's disease. The condition was autosomal dominant, meaning that anyone carrying at least one copy of the mutated presenilin 1 (PSEN1) gene would, like clockwork, lose their memories in their mid-forties.
Sign up for the Live Science daily newsletter nowContact me with news and offers from other Future brandsReceive email from us on behalf of our trusted partners or sponsorsBy submitting your information you agree to the Terms & Conditions and Privacy Policy and are aged 16 or over.Lopera's work in mapping this affected population was invaluable to dementia research, but his most important contribution came just a year before he died in 2024. He co-authored a paper in the journal Nature Medicine that detailed the case of a patient he met in his travels across Colombia. This patient had the PSEN1 gene mutation but lived well into his 60s before developing Alzheimer's. This was the neurological equivalent of a house that stays standing for decades despite cracks in its foundations that should give way.
Lopera discovered that this man's resilient brain was strengthened by another mutation, dubbed COLBOS after the research centers in Colombia and Boston that characterized it.
Improving efficiency
The new research, published in December 2025 in the Journal of the American Chemical Society, has identified exactly how the COLBOS mutation protected the patient's brain for decades.
What to read next-
These genes were thought to lead to blindness 100% of the time. They don't.
-
Only certain types of brain-training exercises reduce dementia risk, large trial reveals
-
'Zombie' cells may drive common form of epilepsy
When the COLBOS variant was first identified in 2023, scientists noted that the mutation altered how a cell signaling protein called reelin functioned. The protein promotes the formation of new connections between brain cells, prevents the toxic tau protein from becoming activated, and prevents amyloid plaques from building up in the brain.
COLBOS altered how reelin binds to another signaling molecule called heparan sulfate, a sugar found on the cell surface of virtually all cell types in humans, including neurons. But how reelin's binding ability affected Alzheimer's progression remained unclear. In the new paper, molecular biologist Chunyu Wang and colleagues at the Rensselaer Polytechnic Institute in New York mapped this process.
Wang's study relied on a technique called surface plasmon resonance, which reveals. how strongly a free-floating molecule — in this case, reelin — binds to a molecule anchored to a sensor surface — in this case, heparan sulfate. Wang's team saw that the COLBOS mutation acted like a molecular glue, strengthening the bonds between the two molecules, suggesting it could cause reelin to accumulate at the surface of neurons in the brain.
This change explained why COLBOS was able to ward off Alzheimer's. When reelin binds to heparan sulfate, the protein becomes localized to the surface of brain cells, where its anti-Alzheimer's signaling is most effective. Here, reelin can more easily ward off cognitive decline by slowing key Alzheimer's disease processes, such as the phosphorylation of the tau protein, said Wang. Phosphorylation destabilizes the normally ordered structure of tau, causing toxic tangles to build up in neurons.
Herz mapped out much of the reelin pathway 20 years ago in a series of papers. Herz's work was in mice, and although his team predicted reelin mutations could be neuroprotective, it was only through Lopera's tireless clinical work that the theory was proven.
Uphill battle
Unfortunately, as Lopera noted, the COLBOS mutation could only delay rather than prevent people with rare Alzheimer's mutations from getting the disease. Herz's theory is that patients with PSEN1 mutations exhibit malfunctions in organelles called the endolysosomal compartments. These are like cellular shredders that chop up troublesome proteins like tau and amyloid. He added that the COLBOS mutation makes the process of feeding these proteins into the shredders more effective.
But as the brain ages, Herz said, the shredder's defects become harder to overcome, despite reelin's effects, leading to Alzheimer’s.
RELATED STORIES— New Alzheimer's drug slightly slows cognitive decline. Experts say it's not a silver bullet.
— Could vaccines prevent and treat Alzheimer's disease?
— Alzheimer's comes in at least 5 distinct forms, study reveals
The findings could have useful implications for future Alzheimer's therapies that delay or prevent disease in the vast majority of patients, including ones without high-risk PSEN1 mutations. Wang pointed to recent research that showed reelin-producing neurons are some of the first to die in Alzheimer's disease. Without these neurons, less reelin is made, toxic waste builds up, and Alzheimer's disease accelerates.
Wang hypothesized that if they could get reelin to act more efficiently at brain cell surfaces, even with less reelin present, that could protect such people from further symptoms. Wang is currently discussing with a colleague at Rensselaer the development of a gene therapy that enhances reelin signaling based on these findings.
Wang pointed out that even if researchers could delay Alzheimer’s by a fraction of the two decades that the COLBOS mutation granted to the Colombian patients, it would be by far the biggest disease improvement ever realized with Alzheimer's. Current drugs on the market for the condition may extend independent living by two to three years, tops, he said, so "20 years is amazing."
Article SourcesPan, L., Song, X., Su, G., Gandy, L. A., Fang, B., Buttaci, M., Gibson, J., Xia, K., Zhang, F., Liu, J., Wang, L., Temple, S., & Wang, C. (2025). N-Sulfated heparan sulfate promotes reelin signaling as a co-receptor. Journal of the American Chemical Society, 147(51), 46773–46779. https://doi.org/10.1021/jacs.5c15573
- 1
- 2
Current page: Page 1
Next Page Page 2
RJ MackenzieLive Science ContributorRJ Mackenzie is an award-nominated science and health journalist. He has degrees in neuroscience from the University of Edinburgh and the University of Cambridge. He became a writer after deciding that the best way of contributing to science would be from behind a keyboard rather than a lab bench. He has reported on everything from brain-interface technology to shape-shifting materials science, and from the rise of predatory conferencing to the importance of newborn-screening programs. He is a former staff writer of Technology Networks.
View MoreYou must confirm your public display name before commenting
Please logout and then login again, you will then be prompted to enter your display name.
Logout Read more
Inherited diseases don't work like we thought they did
From gene therapy breakthroughs to preventable disease outbreaks: The health trends that will shape 2026
Groundbreaking new drug shows promise for treating children with a devastating form of epilepsy
These genes were thought to lead to blindness 100% of the time. They don't.
Only certain types of brain-training exercises reduce dementia risk, large trial reveals
'Zombie' cells may drive common form of epilepsy
Latest in Alzheimers & Dementia
Only certain types of brain-training exercises reduce dementia risk, large trial reveals
Vaccines hold tantalizing promise in the fight against dementia
There's a new blood test for Alzheimer's — here's how it works
Shingles vaccine may directly guard against dementia, study hints
Man nearly guaranteed to get early Alzheimer's is still disease-free in his 70s — how?
'Reanimated' herpes viruses lurking in the brain may link concussions and dementia
Latest in News
Single protein could dramatically alter trajectory of Alzheimer's disease
Falling meteorite smashes hole in roof of German house after spectacular 'fireball' explosion over Europe
2,000-year-old Phoenician coin was used as bus fare in England, but 'how it got there will always be a mystery'
Wildfire season is shifting, but its new time windows vary across Canada and the US drought-prone West
In people with epilepsy, sleeping after a seizure may trigger more seizures
World's smallest QR code can store data for thousands of years — but you need an electron microscope to see it
LATEST ARTICLES
1Falling meteorite smashes hole in roof of German house after spectacular 'fireball' explosion over Europe- 2Gemstone-filled river and striped mountain ridge form massive 'Y' in China's revitalized desert
- 3Exotic prime numbers could be hiding inside black holes
- 42,000-year-old Phoenician coin was used as bus fare in England, but 'how it got there will always be a mystery'
- 5In people with epilepsy, sleeping after a seizure may trigger more seizures
